Question-and-Answer Session
Operator
Thank you. (operator instructions) Our first question comes from Jim Birchenough.
Jim Birchenough - Barclays Capital
Yeah hi guys. Couple of questions on the pipeline. Just on reslizumab, can you give us any details on what percent of patients are going into the open label extension phase of that trial and whether you're seeing any thing, any open label extension that gives you confidence on hitting a primary end point?
And then secondary to that, I am just wondering if you can comment on the end points and the significance both from a regulatory and a commercial standpoint producing eosinophil counts and improving global impressions for these kids. A lot of them get feeds and I am just wondering if you're not really improving feed rates or getting them off GIP, is it really going to support approval and commercially use? Thanks.
Frank Baldino Jr.
Jim, great question, thanks a lot. This is Frank. I will answer the first question and I'll turn the second one over to Lesley about the end points and the regulatory piece of that.
And it's always just the comment in general, it's always difficult to look at anecdotes in open label to know what guys are saying and what that really means overall. And especially people on this call know the caveats of doing that. But nonetheless we are seeing a lot of good things. We don't have specific numbers for you, but majority of the patients are continuing in open label.
I'm going to guess, I never really do that, but since we don't have the real numbers around the table, I'm going to guess it's north of 80% continuing. The second thing that they've noticed is, now they are in open label, they are looking at these kids and again you wait, some of them have eosinophil counts are way down, actually measuring them in open label.
So, we're seeing all the good things you expect to see but there is -- what that means is another question, but what we're not seeing is the stuff we don't want to see. So, from a general anecdotal perspective I think things are winding up the way. We hope they would in the open label setting, and of course we'll know until we break code sometime, but before the end of this year.
Lesley, the second question was about the end points relative to approval for this indication and I think the other part of that question was given the fact that they are on diet, how that would influence some clinical benefit of some sort?
- To read the full transcript on Seeking Alpha, click here »
